このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Seelos Therapeutics 過去の業績

過去基準チェック /26

Seelos Therapeuticsの収益は年間平均-13.1%の割合で減少していますが、 Pharmaceuticals業界の収益は年間減少しています。収益は年間0.4% 65.4%割合で増加しています。

主要情報

-6.6%

収益成長率

22.5%

EPS成長率

Pharmaceuticals 業界の成長	6.0%
収益成長率	64.4%
株主資本利益率	n/a
ネット・マージン	203.1%
前回の決算情報	30 Jun 2024

Recent updates

収支内訳

Seelos Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OTCPK:SEEL 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 24	2	4	11	0
31 Mar 24	2	-27	12	0
31 Dec 23	2	-38	13	0
30 Sep 23	2	-51	13	-33
30 Jun 23	1	-81	12	1
31 Mar 23	1	-73	12	0
31 Dec 22	0	-74	12	0
30 Sep 22	0	-82	17	63
30 Jun 22	0	-73	17	28
31 Mar 22	0	-61	17	33
31 Dec 21	0	-66	15	47
30 Sep 21	0	-45	9	38
30 Jun 21	0	-39	9	29
31 Mar 21	0	-33	8	25
31 Dec 20	0	-19	8	11
30 Sep 20	0	-23	7	0
30 Jun 20	0	-22	6	-9
31 Mar 20	0	-21	6	-7
31 Dec 19	0	-51	6	0
30 Sep 19	0	-42	5	0
30 Jun 19	0	-40	5	9
31 Mar 19	0	-38	4	7
31 Dec 18	0	-3	3	1
30 Sep 18	0	-3	2	1
30 Jun 18	0	-2	1	1
31 Mar 18	0	-2	1	1
31 Dec 17	0	-12	7	3

質の高い収益: SEELには$5.4M } という大きな一回限りの損失があり、過去 12 か月の財務実績が30th June, 2024に影響を及ぼしています。

利益率の向上: SEEL過去に利益を上げました。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: SEEL過去 5 年間で収益を上げており、収益は年間-6.6%増加しています。

成長の加速: SEELは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。

収益対業界: SEEL昨年収益を上げたため、昨年の収益成長をPharmaceuticals業界 ( 13% ) と比較することは困難です。

株主資本利益率

高いROE: SEELの負債は資産を上回っているため、自己資本利益率を計算することは困難です。

Seelos Therapeutics 過去の業績

過去 基準チェック /26

主要情報

最近の業績更新

Recent updates

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index

Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

Seelos Therapeutics, Inc., Annual General Meeting, Sep 27, 2024

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.136948 million.

Seelos Therapeutics Announces 1-for-8 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share of Common Stock for Continued Listing on the Nasdaq Capital Market

Nasdaq to Delist Common Stock of Seelos Therapeutics

Nasdaq to Delist Common Stock of Seelos Therapeutics

Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors

New major risk - Market cap size

Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)

New major risk - Revenue and earnings growth

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.000001 million.

Consensus EPS estimates upgraded to US$0.41 loss

Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

Chief Financial Officer recently bought US$100k worth of stock

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Consensus EPS estimates upgraded to US$0.34 loss

Seelos Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Seelos Therapeutics Receives Non-Compliance Notice From Nasdaq

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 26%

Seelos Therapeutics, Inc. Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

Consensus revenue estimates increase by 80%, EPS downgraded

Seelos Therapeutics, Inc. Announces the Close of Enrollment of Its Registration Directed Study of Sls-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (Asib) in Adults with Major Depressive Disorder (MDD)

Listing Qualifications Staff of Nasdaq Provides Notice to Seelos Therapeutics for Not Regain Compliance with Rule 5550(a)(2) and Not Eligible for Second 180 Calendar Day Compliance Period

Price target decreased by 12% to US$5.50

No longer forecast to breakeven

Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics Doses First Patients in an Ethnobridging Study with Sls-002 (Intranasal Racemic Ketamine)

Seelos Therapeutics, Inc. Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease

Seelos Therapeutics Receives Written Notice of Non-Compliance from Nasdaq

Price target decreased to US$5.80

Seelos Therapeutics Doses First Patient in A Registrational Phase II/III Study of SLS-005 in Spinocerebellar Ataxia

Seelos: Data This Year Is Critical

Seelos Therapeutics Inc. Receives A Research and Development Grant from the Michael J. Fox Foundation for Parkinson's Research for SLS-004

Seelos wins Parkinson’s research grant for gene therapy program

Seelos Therapeutics, Inc. Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in Vitro Gene Therapy Study

Seelos Therapeutics, Inc. Receives Notice of Allowance in U.S. for an Additional Patent for SLS-007

Price target decreased to US$4.25

Seelos Therapeutics Receives Written Notice from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022

Founder recently bought US$57k worth of stock

Price target decreased to US$6.83

Seelos Therapeutics, Inc. Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos: FDA Action Makes It Highly Attractive

Seelos Therapeutics, Inc. announced that it has received $20 million in funding from The Lind Partners, LLC

High number of new and inexperienced directors

High number of new and inexperienced directors

Seelos Therapeutics: Shares Have Finally Found A Floor But Risk Remains

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Director Judith Dunn has left the company

Price target decreased to US$8.58

We're Hopeful That Seelos Therapeutics (NASDAQ:SEEL) Will Use Its Cash Wisely

Seelos: Superior Data, But Early Stage

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $60.000004 million.

Seelos Therapeutics, Inc. Announces Positive Data from the Open-Label Study of SLS-002

New 90-day high: US$4.75

Seelos Therapeutics Announces Completion of Open-Label Patient Enrollment of Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去基準チェック /26